Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Net Cash Flow data on file, last reported at -$89.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 628.86% year-over-year to -$89.6 million in Q1 2026; TTM through Mar 2026 was -$23.9 million, a 133.58% decrease from a year earlier, with the FY2025 full-year figure at $82.7 million, up 74.81% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$89.6 million, down from $101.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for IKT reached as high as $101.0 million in Q4 2025 and fell as low as -$89.6 million in Q1 2026.
• Historically, Net Cash Flow has averaged $519022.2 across 5 years, with a median of -$2.2 million in 2024.
• Across the five-year window, Net Cash Flow soared 1075.7% in 2024 and plunged 1716.49% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $1.4 million in 2022, then slumped by 504.95% to -$5.7 million in 2023, then surged by 1075.7% to $55.6 million in 2024, then soared by 81.64% to $101.0 million in 2025, then plunged by 188.8% to -$89.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$89.6 million in Q1 2026, $101.0 million in Q4 2025, and -$39.5 million in Q3 2025.